Methazolamide (oral)
Orals / systemic · Rx
RxOrals / systemicGlaucoma CaiPreservative-free option
| Strength | 25 / 50 mg tablets |
|---|---|
| Drug class | Systemic carbonic anhydrase inhibitor |
| Mechanism of action | Systemic CAI; longer half-life and less renal effect than acetazolamide, so fewer stones and less hypokalemia, but similar paresthesias and malaise. |
| Indication / reason for use | Chronic adjunctive IOP lowering when a systemic CAI is needed and acetazolamide is poorly tolerated. |
| Usual adult dosing | 25-50 mg two or three times daily. |
| Preservative | N/A , a preservative-free option exists |
| Contact lenses | No lens restriction. |
| Common / important adverse effects | Paresthesias, fatigue, GI upset, taste disturbance, drowsiness; blood dyscrasias and SJS as a class. |
| Contraindications & cautions | Sulfonamide hypersensitivity, hepatic/renal failure, low sodium/potassium, adrenal insufficiency, marked acidosis. |
| Pregnancy / lactation | Avoid. |
| Pregnancy category (older labels) | Category C on the label (the FDA retired letter categories in 2015). From DailyMed labels, checked Nov 2026. |
| Trade names | Neptazane |
| Practice notes | Better tolerated than acetazolamide for the rare patient who needs long-term oral CAI therapy. |
Chair-side reference only. Dosing, contraindications and pregnancy guidance here are not exhaustive. Confirm against the current prescribing information and the patient’s full history before prescribing or advising.